Swedish Orphan Biovitrum Acquires European Rights to Dongbao’s Anemia Drug

November 4, 2010 -- Swedish Orphan Biovitrum has in-licensed European marketing rights to Iron Sucrose Rechon, an anemia drug, from Dongbao Group’s subsidiary, Rechon Life Science Group, a contract manufacturer located in Malmo, Sweden. Sobi will pay a $1.7 million regulatory milestone to Rechon, plus a transfer price and a royalty on net sales. More details....

MORE ON THIS TOPIC